Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Biora Therapeutics, Inc.

< Previous 1 2 Next >
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Achieves ISO 13485 Certification
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Positive Nasdaq Listing Decision
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Funding Agreement with Existing Investors
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.